Telos rx does not currently offer epitalon for compounding. This article explains exactly what that status means today, why it exists, and what it does not imply about the future.
What to know: epitalon is not part of the telos rx program right now. There is no telos rx product page for it, no intake pathway for it, and no confirmed date for when, or whether, that might change. Nothing here should be read as a promise of future availability.
The current status, stated plainly
Epitalon is a synthetic tetrapeptide studied in connection with pineal gland function and, in laboratory research, telomerase activity. Telos rx has not added it to its compounding program, and no telos rx page currently exists for it.
This is a factual, present-tense statement. It describes where telos rx's own review stands today. It is not a prediction, and it should not be read as implying anything about next month, next year, or any specific point in the future.
Patients sometimes search for an epitalon product page on telosrx.com and find nothing. This article exists partly to explain why, since the absence itself can otherwise be confusing.
Why telos rx does not currently offer it
Two related factors explain the current status. First, epitalon's human research base is thinner than the substances telos rx currently offers, drawing largely from a limited number of research groups rather than broad, independently replicated trials.
Second, a 2026 review of research peptides produced non-binding recommendations regarding several substances in this category, epitalon included. A non-binding recommendation is not regulatory approval, and it has not changed telos rx's own program decisions.
For general background on how the FDA evaluates and regulates compounded substances, see the FDA's overview of human drug compounding.
Key takeaway: Epitalon is not part of the telos rx program today, and telos rx has no confirmed timeline for whether that will change.
What "not currently offered" does not mean
It does not mean epitalon is illegal, dangerous beyond what any unregulated substance carries as a general risk, or permanently ruled out. It simply means telos rx has not added it to what it compounds through partner pharmacies.
It also does not mean an announcement is imminent. Telos rx deliberately avoids language suggesting a substance is arriving soon unless that is actually confirmed, and no such confirmation exists for epitalon right now.
Readers who see confident claims elsewhere online that epitalon will soon be widely available should treat those claims with real skepticism, since no verifiable regulatory action currently supports them.
What patients sometimes assume incorrectly
A common assumption is that because epitalon is discussed extensively in longevity and wellness spaces, it must be close to formal availability somewhere. Online visibility and regulatory or clinical readiness are separate things that do not move together.
Another common assumption is that telos rx's silence on epitalon reflects a negative judgment about the underlying science. It reflects telos rx's evaluation process not yet reaching a point where epitalon clears its internal standards, which is a different statement entirely.
Clearing up both assumptions tends to resolve most confusion patients bring to a first conversation about epitalon's status.
How telos rx decides what to add to its program
Telos rx's process considers three things. The strength of published human evidence, the regulatory landscape for compounding a given substance, and whether partner pharmacies can source it reliably at a verified quality standard.
All three factors have to align before telos rx adds anything new. For epitalon, that alignment has not yet occurred, and telos rx does not control the pace at which any of the three factors move forward.
For general context on how complementary and emerging health approaches are typically evaluated, see the NIH NCCIH overview of complementary and integrative health terminology.
How this compares to telos rx's current product lineup
Substances telos rx currently offers, including BPC-157, PT-141, NAD+ nasal spray, and sermorelin, each cleared this same review process. Each has an established compounding pathway and a body of research and clinical use telos rx found sufficient.
Epitalon has not reached that point. This comparison is not a ranking of scientific interest. It reflects where each substance currently stands against telos rx's specific standards for what it will responsibly prepare and dispense.
What would change this status
A stronger human research base would need to develop, along with clearer regulatory footing for compounding and reliable pharmacy sourcing. Telos rx would still need to complete its own internal review after that.
None of these steps has a confirmed timeline. Telos rx will update its own pages if that status changes, rather than speculating about a date it cannot actually predict.
How to verify this status yourself
The most reliable way to confirm epitalon's current status is to check telosrx.com directly. Avoid relying on a third-party summary or forum post, both of which may be outdated.
A search for an epitalon product page on telosrx.com currently returns nothing, because none exists. If that changes in the future, a dedicated page would appear alongside an update to articles like this one.
Independently verifying claims this way is a habit worth applying broadly, not just to epitalon. Outdated or simply inaccurate information circulates widely in wellness spaces, often long after the underlying facts have actually shifted.
What this status means for existing telos rx patients
You may already be a telos rx patient on another protocol, such as BPC-157 or sermorelin. Epitalon's unavailability does not affect your current treatment, since each product on your plan was reviewed and approved independently.
You are welcome to raise interest in epitalon during a message to your care team. A provider can discuss it honestly, note that it is not currently available, and help you think through whether an existing option addresses the same underlying goal.
This kind of conversation does not require booking an appointment. Telos rx's care-team messaging is available to patients without a scheduled visit, which makes raising a question like this easy.
What this status means if you are new to telos rx
You may have found this article while researching epitalon for the first time and are not yet a telos rx patient. The practical takeaway is simple. An epitalon-specific intake does not exist, and starting one is not possible today.
You can still explore whether a currently available product addresses your underlying goal. An asynchronous intake for an available product like sermorelin or NAD+ nasal spray typically takes a few minutes to complete, with provider review often completed within hours rather than days.
There is no obligation to choose an alternative. It is simply an option worth knowing about while epitalon remains outside telos rx's program, and it may address your underlying goal more directly than waiting on uncertain research ever could.
Why this article avoids a projected date
Some readers want a specific answer, even a rough one, about when epitalon might become available. This article intentionally does not provide one, because telos rx does not have one to give honestly.
A guessed date, even offered as a rough estimate, tends to get repeated online as though it were confirmed information. Avoiding that outcome is part of why telos rx is careful and consistent about this kind of language. That consistency spans product pages, articles, and direct messages patients send asking about specific substances.
The accurate, if less satisfying, answer remains that epitalon is under review with no confirmed timeline, and that will stay true until something concrete actually changes. Telos rx would rather be consistently honest about that uncertainty than offer false reassurance that later has to be walked back.
A short summary of where things stand
To recap plainly: epitalon is a synthetic tetrapeptide connected to pineal gland and telomerase research. It is not FDA-approved, telos rx does not currently offer it, and no telos rx product page exists for it today.
A 2026 review produced non-binding recommendations regarding several research peptides, epitalon included, but that is not the same as approval, and it has not changed telos rx's program. No confirmed timeline exists for when, or whether, epitalon might be added later.
Everything in this article reflects the current, factual status. It is not a prediction, and it is not an implicit promise about anything arriving in the future.
Which is right for you
If your underlying interest is aging, recovery, or general wellness support, sermorelin is a compounded option telos rx currently offers, as low as $125 a month.
Telos rx also currently offers NAD+ nasal spray and BPC-157, each compounded, not FDA-approved, and available through an asynchronous intake reviewed by a licensed provider.
If sermorelin sounds like a reasonable fit, start an online visit to see if it is appropriate for you.
Frequently Asked Questions
Does telos rx currently offer epitalon?
No. Epitalon is not part of the telos rx compounding program right now, and there is no telos rx product page for it.
Is epitalon coming to telos rx soon?
Telos rx has no confirmed timeline for adding epitalon. Claims suggesting imminent availability are not supported by anything telos rx has confirmed.
Does not offering epitalon mean it is dangerous?
No. It means telos rx has not added it to its program. That reflects evidence, regulatory, and sourcing standards, not a judgment that it is unsafe.
Did the 2026 peptide review change epitalon's status?
No. That review produced non-binding recommendations, not regulatory approval, and telos rx's program status for epitalon has not changed.
How does telos rx decide what to add to its program?
It weighs human research strength, regulatory footing, and reliable pharmacy sourcing, then completes its own internal review before adding anything new.
What can I start with telos rx today instead?
Telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin, each through an asynchronous intake reviewed by a licensed provider.
This article is general information, not medical advice, and does not replace guidance from your own provider. Compounded medications are not FDA-approved. Telos rx works with partner compounding pharmacies that are LegitScript-certified.
Epitalon is not currently offered by telos rx.